EN DE

Healthconn Corp (6665) Fair Value & Analysis

Healthcare · TW · Market cap 882M TWD

HC Healthconn Corp 6665 · TWO
Price18.70 TWD
Fair Value4.88 TWD
Upside-73.9%
Quality54/100
Watch Healthconn Corp for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 0.7% net margin
generates free cash flow
0.76% dividend yield
Trails peers (2/12)
Narrow moat 22/100
Evidence: High Range 3.05 TWD – 6.62 TWD Share as image

Fair value as of: Jul 23, 2026

From 26 valuation models · updated 18 days ago

Share price −11.0% over the past month.

A solid business, but screening 74% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (6.62 TWD). The favourable scenario is already priced in.
  • Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range (3.05 TWD to 6.62 TWD) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

60.68 TWD 17.35 TWD Fair Value 4.88 TWD Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 17.35 TWD – 60.68 TWD · fair‑value band 3.05 TWD – 6.62 TWD · the 18.70 TWD price screens above the 4.88 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Healthconn Corp (6665) currently trades at 18.70 TWD, while our model-based Fair Value estimate is 4.88 TWD, implying the stock looks roughly 73.9% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Healthconn Corp generated revenue of 1.1B TWD at a net margin of 0.7%. Revenue declined 11.1% year over year. It earns a return on equity of 0.9%. The balance sheet holds a net cash position of 285M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 3.05 TWD (bear case) to 6.62 TWD (bull case); at 18.70 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at -74%, 6665 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 13.18 TWD 12.19 TWD 8.06 TWD 76
Growth DCF 15.96 TWD 20.76 TWD 27.31 TWD 72
Gordon GGM 5.44 TWD 9.80 TWD 13.49 TWD 70
All 26 models by family
DCF Models
FCF DCF 16.00 TWD 21.24 TWD 28.73 TWD 38
Owner Earnings 14.00 TWD 18.13 TWD 24.03 TWD 31
5Y Revenue Exit 10.55 TWD 11.46 TWD 12.41 TWD 39
5Y EBITDA Exit 16.87 TWD 23.87 TWD 32.29 TWD 41
5Y P/E Exit 11.86 TWD 14.03 TWD 16.30 TWD 38
10Y Revenue Exit 12.62 TWD 14.05 TWD 15.70 TWD 36
10Y EBITDA Exit 16.40 TWD 22.13 TWD 30.21 TWD 37
10Y P/E Exit 13.42 TWD 15.73 TWD 18.54 TWD 35
Earnings-Based
Graham-Dodd 1.26 TWD 4.88 TWD 6.62 TWD 54
Lynch FV 1.20 TWD 1.71 TWD 2.22 TWD 50
PEG = 1.0 1.20 TWD 1.71 TWD 2.22 TWD 46
EPV 6.81 TWD 6.84 TWD 6.88 TWD 59
Dividend Discount
Gordon GGM 5.44 TWD 9.80 TWD 13.49 TWD 70
DDM Multi-Stage 5.44 TWD 8.95 TWD 10.47 TWD 61
Multiples
P/E Multiple 3.05 TWD 4.07 TWD 5.09 TWD 63
P/S Multiple 2.36 TWD 3.15 TWD 3.93 TWD 58
P/B Multiple 2.36 TWD 3.15 TWD 3.93 TWD 55
EV/EBIT 7.41 TWD 7.71 TWD 8.01 TWD 53
EV/EBITDA 18.67 TWD 22.71 TWD 26.76 TWD 54
EV/Revenue 7.16 TWD 7.43 TWD 7.70 TWD 43
Asset-Based
NCAV (Graham) 10.21 TWD 13.68 TWD 20.42 TWD 50
Growth DCF
Growth DCF 15.96 TWD 20.76 TWD 27.31 TWD 72
Rev-Margin DCF 10.55 TWD 11.64 TWD 13.01 TWD 67
Economic Profit
Residual Income 13.18 TWD 12.19 TWD 8.06 TWD 76
ROIC Compounder 6.81 TWD 6.84 TWD 6.88 TWD 67
Growth Earnings
Growth-Adj P/E 2.21 TWD 3.16 TWD 4.11 TWD 68

Widest divergence: DCF Models (15.73 TWD) versus Earnings-Based (1.71 TWD). Highest evidence: Residual Income (76).

Notify me when 6665 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 1.1B TWD
Revenue growth (YoY) -11.1%
Net margin 0.7%
Return on equity 0.9%
Free cash flow 43.1M TWD FY2025
P/E ratio 102.4
More key figures
Operating margin 1.4%
EPS (TTM) 0.1900 TWD
EPS growth (YoY) -34.6%
Net cash 285M TWD FY2023

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 54/100

Of which business quality 54 · Market factors (momentum, volatility) 34

Profitability 26
Margins and returns on capital today
Quality Growth 22
Are margins and returns improving?
Cashflow 53
Earnings quality: real cash, not paper profit
Fin. Strength 63
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 73
Calm price path (market factor)
Momentum 23
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Healthconn Corp. engages in the health services management in Taiwan and China. The company engages in the provision of health promotion consulting services, precision medicine health management services; genetic testing; and sales of molecular biology, genetics, microbial life science testing, precision instruments, and reagents.

Full company description

Healthconn Corp. engages in the health services management in Taiwan and China. The company engages in the provision of health promotion consulting services, precision medicine health management services; genetic testing; and sales of molecular biology, genetics, microbial life science testing, precision instruments, and reagents. It also offers diagnostic solutions, including microbiology, total lab automation, molecular biology, life sciences, laboratory information systems, and environment and safety solutions; and warehouse and logistics solutions. Healthconn Corp. was founded in 2009 and is based in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Healthconn Corp reported revenue of 1.1B TWD in FY2025 versus 1.4B TWD in FY2021, a compound −4.6%/yr. Reported net income was 8.4M TWD in FY2025, compounding −31.2%/yr from FY2021.

Growth Quality 79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
1.1B TWD
Latest YoY
−9.8%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−9.9%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+30.1%
Avg. growth/yr (9Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+10.5%
Revenue −4.6%/yr
FY21 1.4B TWD
FY22 1.5B TWD
FY23 1.3B TWD
FY24 1.3B TWD
FY25 1.1B TWD
Net income −31.2%/yr
FY21 37.4M TWD
FY22 25.4M TWD
FY23 2.4M TWD
FY24 19.2M TWD
FY25 8.4M TWD

6665 screens 74% overvalued. Compare with UnitedHealth Group →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Healthconn Corp Fair Value". https://www.fairvalue-calculator.com/stock/6665

Peer Group

Healthcare Plans · 15 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 54 · Below median
Fair Value upside −74% · Bottom 25%
Return on equity (TTM) 1% · Bottom 25%
Return on assets 0% · Bottom 25%
Net margin (TTM) 1% · Below median
Operating margin (TTM) 1% · Bottom 25%
Revenue growth -11% · Bottom 25%

Valuation Multiples vs Healthcare Plans median · lower = cheaper

P/E (TTM) 102.4× · Pricier than 75% of peers
P/B 0.95× · Cheaper than 75% of peers
P/S (TTM) 0.78× · Pricier than median
P/FCF 0.6× · Cheaper than 75% of peers
EV/EBITDA 21.7× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 35
FUTURE 0 · sector 23
PAST 4 · sector 41
HEALTH 0 · sector 65
DIVIDEND 15 · sector 0

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
UnitedHealth Group UNH $423.38 $292.06 -31%
CVS Health Corporation CVS $104.15 $42.54 -59%
Elevance Health, Inc ELV $372.85 $431.40 +16%
The Cigna Group CI $304.50 $495.42 +63%
Humana Inc HUM $400.00 $127.61 -68%
Centene Corporation CNC $66.61 $111.96 +68%
Molina Healthcare, Inc MOH $233.31 $199.31 -15%
Oscar Health, Inc OSCR $29.10 $58.20 +100%
Alignment Healthcare, Inc ALHC $20.60 $2.37 -88%
Progyny, Inc PGNY $31.93 $16.44 -49%

Compare Healthconn Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Healthconn Corp (6665) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 4.88 TWD versus a price of 18.70 TWD, about −74% (overvalued).
What is the fair value of 6665?
Our model-based fair value for Healthconn Corp is 4.88 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 18.70 TWD.
What is the quality score of 6665?
Healthconn Corp has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Healthconn Corp (6665)?
Healthconn Corp reported trailing-twelve-month revenue of about 1.1B TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 6665?
The net profit margin of Healthconn Corp is about 0.7%, meaning it keeps roughly 0.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Healthconn Corp and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.